Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign a consent form and are able to attend the required visits and follow the study procedures
• People who have at least one tumour that can be measured using standard imaging criteria (called RECIST v1.1)
• People aged 18 or older (any gender)
• People whose general physical functioning is rated at a good to mildly limited level on a standard scale used by doctors (ECOG score of 0 or 1)
• People whose doctors expect them to survive for at least 12 weeks
• People whose blood counts and organ function (such as liver and kidneys) are at adequate levels
• People who are able to use effective contraception throughout treatment and for 6 months after treatment ends — this applies to women who could become pregnant, and to men whose partners could become pregnant
• People whose tumour tissue has tested positive for a protein called CLDN18.2, confirmed by a central laboratory

Who may not be able to join:

• People who are currently taking part in another interventional clinical trial (trials where a treatment is being tested), unless it is an observational study or a survival follow-up phase only
• People who have taken a strong CYP3A4 inhibitor (a type of medication that affects how other drugs are processed by the body) within 2 weeks or 5 half-lives before starting the trial drug, whichever is the longer period (confirm with trial site)
• People who have received anti-cancer treatment within 4 weeks or 5 half-lives of that treatment before starting the trial drug, whichever is the shorter period
• People who have received radiotherapy aimed at treating or relieving symptoms within 2 weeks before starting the trial drug
• People who have had a biliary stent placed (a small tube inserted into the bile duct) within 7 days before starting the trial drug
• People who are planning to receive other anti-cancer treatments while on the trial drug
• People who have received a live vaccine within 4 weeks before starting the trial drug, or who plan to receive a live vaccine during the study
• People who have had major surgery within 4 weeks before starting the trial drug, or who have wounds, ulcers, or fractures that have not healed, or who plan to have major surgery during the study
• People who have not yet recovered from side effects of previous treatments to a mild or resolved level before starting the trial drug
• People who have had a hole or abnormal opening (perforation or fistula) in their digestive tract within the past 6 months that was not fully resolved by surgery
• People who have a blockage at the stomach outlet (pyloric obstruction) or who experience repeated vomiting that does not go away
• People who have had a stent placed in the digestive tract or airway (confirm with trial site)
• People who have brain or spinal cord metastases that are currently causing symptoms
• People who have bone metastases that put them at risk of spinal cord compression or paralysis
• People who have lung disease affecting the tissue between the air sacs (interstitial lung disease) that requires steroid treatment, or a history of such conditions, severe lung function problems, or uncontrolled lung diseases such as pulmonary fibrosis or severe radiation-related lung damage
• People who have other serious medical conditions that are not well controlled (confirm with trial site)
• People who have a history of another primary cancer (a separate, unrelated cancer)
• People with a known history of immune system deficiency
• People who have previously received an organ transplant or a stem cell transplant from another person
• People who have previously been treated with a type of cancer drug called a topoisomerase inhibitor-based antibody-drug conjugate
• People who have a known allergy to the study drug or its ingredients (as applicable to the treatment being received in the trial)
• People for whom the study drug is medically contraindicated (meaning their doctor has determined the drug should not be used for them)
• People who have previously had to permanently stop taking the relevant study drug due to side effects
• People who are pregnant or breastfeeding
• People whom the trial doctors consider unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.